Effect of Thymus vulgaris, Myrtus communis and nystatin on Candida albicans

Candida albicans is the most frequent etiological agent of oral candidiasis. This study was done to compare the anticandidal effect of Thymus vulgaris and Myrtus communis to nystatin on Candida albicans. In this laboratory study thirty-two strains of Candida albicans isolated from patients with oral candidiasis. Yeast suspension of Candida yeast cells was provided, subsquntly a serial dilution from Thymus vulgaris and Myrtus communis and Nystatin in Sabouraud Dextrose Agar [SDA] medium were prepared. Then a loop of Candida suspension was cultured on all of the solid media and was incubated at 25°C. The findings of fungus growing were recorded during 7 days. MIC of Thymus vulgaris, Myrtus communis L, mix of these essences and Nystatin was 0.390 microl/ml, 12.5 microl/ml, 0.78 microl/ml and 160 IU/ml, respectively. Thymus vulgaris contained antifungal activity against Candida albicans, but Myrtus communis demonstrated a very low activity against Candida albicans

Comparative study of bioavailabilities of three formulations of cotrimoxazole tablets

Bioavailablities of three brands of Cotrimoxazole tablets, from local and international firms, were studied in eight healthy human volunteers by double blind cross - over design. Bioavailability of Sulphamethoxazole was determined from area under the curve of plasma concentrations versus time, while that of Trimethoprim was determined by measuring the cumulative amount of unchanged drug excreted in urine for 48 hours. We did not find any significant differences in their bioavailabilities and that they should be clinically equally effective

Comparison of bio-availability of different brands of chloramphenicol currently on the market

Different drug manufacturers claim better qualities and bioavailability of their products as compared to identical strengths of these very drugs manufactured by their rivals. In view of this confusion, bioavailability of four different brands of chloramphenicol was measured in ninety six albino rabbits. The relative bioavailabilities were determined by measuring area under curve [AUC] of plasma concentrations versus time which were 100%, 85.34%, 76.14% and 83.83% for the brands A, B, C, and D respectively. However, the plasma concentrations remained well above [4-5 times] the minimal inhibitory concentrations [MIC] against sensitive organisms for a reasonable period of time with all the four brands. Therefore, we presume that they should not differ in their clinical efficacies